Christopher J. Kane

Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions

Automated Patient-level Prostate Cancer Detection with Quantitative Diffusion Magnetic Resonance Imaging

Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma

Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials

Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate

Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance

Obesity, race, and long‐term prostate cancer outcomes

Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation

Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer

Radiative leptonic decays on the lattice

Nerve-targeted probes for fluorescence-guided intraoperative imaging

Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens

Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2–3) and Implications for Risk Stratification: A Systematic Review

Thresholds for <scp>PSA</scp> doubling time in men with non‐metastatic castration‐resistant prostate cancer

Predictors of operative time during radical retropubic prostatectomy and robot‐assisted laparoscopic prostatectomy

Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence

Prostate Cancer, Version 1.2016

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH

Predictors of Time to Metastasis in Castration-resistant Prostate Cancer

Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI

Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy

Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.

Prostate Cancer, Version 2.2014